[1. Supraporn S. First annual meeting Thai Breast Disease Society. Bangkok: Thai Breast Breast Society; 2007.]Search in Google Scholar
[2. Attasara P BR. Hospital-based cancer registry. Bangkok: National Cancer Institute; 2007.]Search in Google Scholar
[3. Nakamura S. Axillary lymph node dissection in sentinel node positive breast cancer: is it necessary? Curr Opin Obstet Gynecol. 2013 Feb 19. [Epub ahead of print].10.1097/GCO.0b013e32834f3608]Search in Google Scholar
[4. Moncayo VM, Aarsvold JN, Grant SF, Bartley SC, Alazraki NP. Status of sentinel lymph node for breast cancer. Semin Nucl Med. 2013; 43:281-93.10.1053/j.semnuclmed.2013.02.004]Open DOISearch in Google Scholar
[5. Wang Z, Wu LC, Chen JQ. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011; 129:675-89.10.1007/s10549-011-1665-1]Search in Google Scholar
[6. Park HS, Chae BJ, Song BJ, Jung SS, Han W, Nam SJ, et al. Effect of axillary lymph node dissection after sentinel lymph node biopsy on overall survival in patients with T1 or T2 node-positive breast cancer: report from the Korean Breast Cancer Society. Ann Surg Oncol. 2013 Dec 7.10.1245/s10434-013-3350-6]Search in Google Scholar
[7. Feig BW BD, Fuhrman GM. Anderson surgical oncology handbook. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p.23-59.]Search in Google Scholar
[8. Meretoja TJ, Audisio RA, Heikkila PS, Bori R, Sejben I, Regitnig P, et al. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat. 2013; 138:817-27.10.1007/s10549-013-2468-3]Search in Google Scholar
[9. Noguchi M, Morioka E, Ohno Y, Nakano Y, Kosaka T. The changing role of axillary lymph node dissection for breast cancer. Breast Cancer. 2012; 20:41-6.10.1007/s12282-012-0416-4]Open DOISearch in Google Scholar
[10. Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008; 15:1996-2005.10.1245/s10434-008-9909-y]Open DOISearch in Google Scholar
[11. Bafford A, Gadd M, Gu X, Lipsitz S, Golshan M. Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma. Am J Surg. 2010; 200:374-7.10.1016/j.amjsurg.2009.10.012]Search in Google Scholar
[12. Sanuki N, Takeda A, Amemiya A, Ofuchi T, Ono M, Ogata H, et al. Outcomes of clinically node-negative breast cancer without axillary dissection: can preserved axilla be safely treated with radiation after a positive sentinel node biopsy? Clin Breast Cancer. 2012; 13: 69-76.10.1016/j.clbc.2012.09.005]Open DOISearch in Google Scholar
[13. Boyages J, Winch C. Axillary versus sentinel-lymphnode dissection for micrometastatic breast cancer. Lancet Oncol. 2013; 14:e250-1.10.1016/S1470-2045(13)70218-3]Open DOISearch in Google Scholar
[14. Wells BJ, Quan ML, Coyte PC. The ever-diminishing role of axillary lymph node dissection in breast cancer. Breast J. 2013; 19:691-2.10.1111/tbj.12196]Open DOISearch in Google Scholar
[15. Orang E, Marzony ET, Afsharfard A. Predictive role of tumor size in breast cancer with axillary lymph node involvement - can size of primary tumor be used to omit an unnecessary axillary lymph node dissection? Asian Pac J Cancer Prev. 2013; 14:717-22.]Search in Google Scholar
[16. Ogawa Y, Ikeda K, Ogisawa K, Tokunaga S, Fukushima H, Inoue T, et al. Outcome of sentinel lymph node biopsy in breast cancer using dye alone: a single center review with a median follow-up of 5 years. Surg Today. 2013 Sep 26.10.1007/s00595-013-0728-9]Search in Google Scholar
[17. Zengel B, Yararbas U, Sirinocak A, Ozkok G, Denecli AG, Postaci H, et al. Sentinel lymph node biopsy in breast cancer: review on various methodological approaches. Tumori. 2013; 99:149-53.10.1177/030089161309900205]Search in Google Scholar
[18. Kantaraksa N, Kongdan Y, Suvikapakornkul R, Wasutit Y, Chirappapha P, Lertsithichai P. The relative false negative rate of isosulfan blue in detecting sentinel lymph nodes in early breast cancer. J Med Assoc Thai. 2012; 95:181-5.]Search in Google Scholar
[19. Gill G. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 2009; 16:266-75.10.1245/s10434-008-0229-z]Open DOISearch in Google Scholar
[20. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006; 106:4-16.10.1002/cncr.21568]Open DOISearch in Google Scholar
[21. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8:881-8.10.1016/S1470-2045(07)70278-4]Open DOISearch in Google Scholar
[22. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98:599-609.10.1093/jnci/djj15816670385]Open DOISearch in Google Scholar
[23. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251:595-600.10.1097/SLA.0b013e3181c0e92a20195151]Search in Google Scholar
[24. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del Bianco P, et al. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008; 247:207-13.10.1097/SLA.0b013e31812e6a7318216523]Search in Google Scholar
[25. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001, Philadelphia, Pennsylvania. Hum Pathol. 2002; 33:579-89.10.1053/hupa.2002.12411712152156]Search in Google Scholar
[26. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349:546-53.10.1056/NEJMoa012782]Search in Google Scholar
[27. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23:7703-20.10.1200/JCO.2005.08.001]Open DOISearch in Google Scholar
[28. O’Hea BJ, Hill AD, El-Shirbiny AM, Yeh SD, Rosen PP, Coit DG, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan- Kettering Cancer Center. J Am Coll Surg. 1998; 186: 423-7.10.1016/S1072-7515(98)00060-X]Search in Google Scholar
[29. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998; 227:645-51; discussion 51-3.10.1097/00000658-199805000-0000511913399605656]Search in Google Scholar
[30. Canavese G, Gipponi M, Catturich A, Vecchio C, Tomei D, Nicolo G, et al. Technical issues and pathologic implications of sentinel lymph node biopsy in early-stage breast cancer patients. J Surg Oncol. 2001; 77:81-7; discussion 8.10.1002/jso.107411398158]Open DOISearch in Google Scholar
[31. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220:391-8; discussion 8-401.10.1097/00000658-199409000-0001512344008092905]Search in Google Scholar
[32. Simmons RM, Smith SM, Osborne MP. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Breast J. 2001; 7: 181-3.10.1046/j.1524-4741.2001.007003181.x11469932]Open DOISearch in Google Scholar
[33. Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003; 10:242-7.10.1245/ASO.2003.04.02112679308]Open DOISearch in Google Scholar
[34. Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol. 2002; 9:169-76.10.1007/BF0255737011888875]Open DOISearch in Google Scholar
[35. Zavagno G, Meggiolaro F, Rossi CR, Casara D, Pescarini L, Marchet A, et al. Subareolar injection for sentinel lymph node location in breast cancer. Eur J Surg Oncol. 2002; 28:701-4.10.1053/ejso.2002.134012431465]Open DOISearch in Google Scholar
[36. Kuerer HM, Wayne JD, Ross MI. Anaphylaxis during breast cancer lymphatic mapping. Surgery. 2001; 129: 119-20.10.1067/msy.2001.111212]Open DOISearch in Google Scholar
[37. Sleth JC. [Anaphylaxis due to patent blue. Time to change dye?] Ann Fr Anesth Reanim. 2008; 27:515. (in French)10.1016/j.annfar.2008.05.004]Open DOISearch in Google Scholar
[38. Nason KS, Anderson BO, Byrd DR, Dunnwald LK, Eary JF, Mankoff DA, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000; 89:2187-94.10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#]Open DOISearch in Google Scholar
[39. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001; 182:312-5.10.1016/S0002-9610(01)00718-8]Open DOISearch in Google Scholar
[40. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006; 93:539-46.10.1002/bjs.5209]Open DOISearch in Google Scholar
[41. Reitsamer R, Menzel C, Glueck S, Rettenbacher L, Weismann C, Hutarew G. Sentinel lymph node biopsy is precise after primary systemic therapy in stage IIIII breast cancer patients. Ann Surg Oncol. 2010;17 Suppl 3:286-90.10.1245/s10434-010-1246-2]Open DOISearch in Google Scholar
[42. Shimazu K, Noguchi S. Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer. Surg Today. 2011; 41:311-6.10.1007/s00595-010-4404-z]Open DOISearch in Google Scholar
[43. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer - results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006; 99:203-8. 10.1007/s10549-006-9192-1]Open DOISearch in Google Scholar